PITTSBURGH , Sept. 04, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing medicines to treat rare skin diseases, today announced the initiation of the Phase 1/2 study of KB105 in transglutaminase-1 (TGM1) deficient autosomal recessive

PITTSBURGH , Aug. 27, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish S.

FDA grants RMAT designation for KB103 to treat dystrophic epidermolysis bullosa (DEB) Announced positive results from Phase 2 trial (“GEM-2”) of KB103 Submitted an IND application to initiate a Phase 1/2, first in-human trial of KB105 to treat patients with TGM1-deficient autosomal recessive

PITTSBURGH , July 01, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing medicines to treat skin diseases, today announces that it has been added to the Russell 2000 ®  Index, effective after the stock market close on June 28, 2019

PITTSBURGH , June 24, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq: KRYS) (the “Company”), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced that it has priced the previously announced

PITTSBURGH , June 24, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech , Inc. (Nasdaq: KRYS) (the “Company”), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced that it has commenced an underwritten public

Safety data from all patients show that KB103 was well tolerated with no adverse events reported Five out of six wounds treated with KB103 in the Phase 2 trial closed 100% during the trial The average time to complete 100% wound closure on KB103 treated wounds in Phase 2 trial was 23 days With the

KB105 is a new gene therapy candidate engineered with a Transglutaminase-1 (TGM1) gene construct to treat TGM1 deficient autosomal recessive congenital ichthyosis KB105 is the second pipeline product based on the STAR-D platform and is part of a growing pipeline of gene therapy candidates for skin

PITTSBURGH , May 15, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing medicines to treat dermatological diseases, today announced that Krish S. Krishnan , chairman and chief executive officer, will be presenting at the upcoming RBC

EMA grants PRIME eligibility for KB103 (bercolagene telserpavec)  to treat dystrophic epidermolysis bullosa Krystal Biotech announces five presentations of clinical and preclinical data at the Society for Investigative Dermatology (“SID”) Annual Meeting PITTSBURGH , May 06, 2019 (GLOBE NEWSWIRE) --